Spartalizumab(Spartalizumab) - 药物靶点：PD-1_在研适应症：转移性黑色素瘤，不可切除的黑色素瘤，食管腺癌_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

Spartalizumab (genetical recombination) (JAN)、Spartalizumab (USAN/INN)、NVP-LZV184

+ [2]

靶点

PD-1

作用方式

抑制剂

作用机制

PD-1抑制剂(细胞程序性死亡-1抑制剂)

治疗领域

肿瘤消化系统疾病内分泌与代谢疾病+ [9]

在研适应症

转移性黑色素瘤不可切除的黑色素瘤食管腺癌+ [44]

非在研适应症

急性髓性白血病晚期肝细胞癌晚期神经内分泌癌+ [42]

原研机构

Novartis Pharma AG

在研机构

Novartis Pharma AG

Novartis Pharmaceuticals Corp.

Novartis AG

+ [1]

非在研机构

诺华（中国）生物医学研究有限公司

北京诺华制药有限公司Novartis Pharma Services AG

权益机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)临床1期

特殊审评孤儿药 (美国)

登录后查看时间轴

结构/序列

Sequence Code 9921158L

来源: *****

Sequence Code 9921288H

来源: *****

关联

74

项与 Spartalizumab 相关的临床试验

NCT07157345

/ Recruiting临床1期IIT

A Study on the Safety, Tolerability, and Efficacy of PDR-001 Injection for Bilateral Stereotactic Subthalamic Nucleus (STN) Clearance of α-synuclein

Parkinson's disease (PD) poses a severe threat to human health, and its incidence is rising year by year. Current therapeutic options are limited by significant shortcomings. Pathological aggregation of α-synuclein and the consequent death of dopaminergic neurons are the primary drivers of PD pathogenesis. While siRNA-mediated knockdown of α-synuclein can offer some protection to dopaminergic neurons, its clinical utility is hampered by low cellular uptake, off-target effects, and transient activity. These drawbacks underscore the urgent need for novel strategies that can efficiently and specifically degrade α-synuclein to delay or even halt PD progression.
Our prior work identified tat-βsyn-deg (PDR-001), a three-segment peptide that selectively targets α-synuclein. When packaged into AAV9 capsids and delivered via bilateral stereotaxic injection into the subthalamic nucleus, this peptide effectively reduces α-synuclein within the target region. Pre-clinical studies in both human-α-synuclein-expressing mice and non-human primate models of PD have demonstrated robust α-synuclein clearance and marked improvements in motor deficits (see Research Foundation).
The present project will advance PDR-001 into first-in-human studies to evaluate safety and explore preliminary efficacy. Unlike conventional symptomatic therapies, this approach targets the root cause of PD, setting the stage for disease-modifying treatment. Successful translation would establish a new therapeutic paradigm capable of slowing or preventing PD progression.

开始日期2025-10-20

申办/合作机构

上海交通大学医学院附属瑞金医院

NCT05201066

/ Active, not recruiting临床2期

An Open-label, Multicenter, Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

This study is intended to collect safety data from participants who completed the parent protocols but are still benefiting from study treatment. The study population consists of participants who tolerate study treatment of the parent studies. Collecting safety information from long-term exposure might offer the unique opportunity to detect rare Adverse Events.

开始日期2023-02-13

申办/合作机构

Novartis Pharmaceuticals Corp.

NL-OMON51829

/ RecruitingN/A

An open-label, multi-center rollover protocol for continued characterization of safety and tolerability for subjects who have participated in a Novartis-sponsored spartalizumab study as single agent or in combination with other study treatments - CPDR001X2X01B

开始日期2022-08-30

申办/合作机构

Novartis AG

100 项与 Spartalizumab 相关的临床结果

登录后查看更多信息

100 项与 Spartalizumab 相关的转化医学

登录后查看更多信息

100 项与 Spartalizumab 相关的专利（医药）

登录后查看更多信息

34

项与 Spartalizumab 相关的文献（医药）

2026-03-01·EUROPEAN JOURNAL OF CANCER

Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): Results from the GASPAR phase 2 study

Article

作者: Corbinais, Stéphane ; Piessen, Guillaume ; Guilloit, Jean-Marc ; Bouche, Olivier ; Parzy, Aurélie ; Desgrippes, Romain ; Samalin, Emmanuelle ; Le Sourd, Samuel ; Lequesne, Justine ; Tougeron, David ; Guimbaud, Rosine ; Leconte, Alexandra ; Hiret, Sandrine ; Dahan, Laetitia ; Galais, Marie-Pierre ; Dos Santos, Mélanie ; Soularue, Emilie ; Borg, Christophe ; Pernot, Simon ; Varatharajah, Sharmini ; Brachet, Pierre-Emmanuel ; Dorbeau, Marine ; Clarisse, Bénédicte

PURPOSE:

Perioperative chemotherapy with FLOT is a standard of care for patients with resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma. This trial evaluated the anti-PD-1 monoclonal antibody spartalizumab combined with FLOT as perioperative treatment for resectable patients.

PATIENTS AND METHODS:

GASPAR is a multicenter, single-arm, Simon two-stage phase 2 trial. Patients with untreated localized gastric or GEJ adenocarcinoma considered resectable (≥ cT2 or cN+) received 4 pre- and post-operative cycles of FLOT and 2 pre- and post-operative cycles of spartalizumab. The main endpoint was the rate of pathological complete regression (pCR) according to the Becker criteria, requiring 67 patients (H0/H1 =10/23 %, α=5 %, β=20 %).

RESULTS:

Overall, 68 patients were included: men (78 %), median age 63 years [range 31-79], cT3 51 %, GEJ 60 %, cN+ 58 %. Treatment was started in 67 patients. Delayed FLOT administration for toxicity and dose reduction concerned 14 (21 %) and 28 (42 %) patients, respectively. Surgery was R0 in 62 (95 %) of the patients operated on. Among 64 patients assessable for efficacy, pCR was observed in 20 patients (31 %), and major pathological response in 12 patients (19 %), meaning a major response rate of 50 %. Five patients developed grade 3 immune-mediated adverse events. One death related to pneumocystis occurred. Severe post-surgery complications occurred in 15 patients (23 %). After a median follow-up of 30 months [range 4-42], OS and DFS at 2 years were 86 % [77.8-94.9] and 77.5 % [68.1-88.2], respectively.

CONCLUSIONS:

Spartalizumab combined with FLOT shows high efficacy as perioperative treatment in patients with resectable gastric cancer, and an acceptable safety profile.

TRIAL REGISTRATION:

ClinicalTrials.gov Identifier: NCT04736485.

2025-10-01·ESMO Open

Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial

Article

作者: Amillano, K ; Sanfeliu, E ; González, B ; Martín-Liberal, J ; Paz-Ares, L ; Garralda, E ; Ciruelos, E ; González, X ; Aguirre, Á ; Castillo, O ; Pascual, T ; Vivancos, A ; Saura, C ; Conte, B ; Cervantes, A ; Villacampa, G ; Victoria, I ; Hierro, C ; Galván, P ; Mulero-Sánchez, A ; Seguí, E ; Gavilá, J ; Ferrero-Cafiero, J M ; Walbaum, B ; Brasó-Maristany, F ; Prat, A ; Indacochea, A ; Blasco, P ; Salvador, F ; Racca, F ; Cejalvo, J M ; Mesía, R ; Pardo, F ; Juan, M ; Arance, A ; Tabernero, J ; Sirenko, V ; Izarzugaza, Y ; López-González, A ; Felip, E

BACKGROUND:

Immune checkpoint inhibitors (ICIs) have transformed the treatment of solid tumors, yet responses vary across cancer types, highlighting the need for reliable pan-cancer biomarkers. Prior retrospective studies identified PD1 mRNA as a promising predictor of anti-PD1 response, but prospective validation was lacking.

PATIENTS AND METHODS:

The SOLTI-1904 ACROPOLI trial was a non-randomized, open-label, multicenter phase II study designed to evaluate the efficacy of anti-PD1 monotherapy in patients with advanced solid tumors and high PD1 mRNA expression (cohort 1). An exploratory cohort also enrolled PD1-low tumors from cancer types with known ICI sensitivity (cohort 2). Between April 2021 and March 2022, 1003 patients across 33 cancer types were prescreened; 10.6% were classified as PD1-high. A total of 56 PD1-high and 15 PD1-low cases were enrolled to receive spartalizumab (400 mg intravenously every 4 weeks). The primary endpoint was objective response rate (ORR) in PD1-high tumors. Cohorts 1 and 2 were closed early due to discontinuation of spartalizumab development, before reaching full accrual.

RESULTS:

In the PD1-cohort, which included heavily pretreated tumors (median two prior lines) across 19 histologies, the ORR was 17.9% (95% confidence interval 7.8% to 27.9%). Among patients with tissue samples collected within 12 months of treatment, the ORR increased to 33.3%. The clinical benefit rate (partial response or stable disease ≥24 weeks) was 30.4%. Responses occurred in cancers typically resistant to ICIs, including pancreatic and microsatellite-stable colorectal cancers. No new safety signals were identified. Programmed death-ligand 1 expression by immunohistochemistry was significantly associated with response, whereas exploratory analyses identified additional potential biomarkers, including B cell gene signatures and tumor proliferation markers.

CONCLUSIONS:

PD1 mRNA may help identify immunogenic tumors across cancer types. However, the trial's early closure and exploratory nature warrant further validation. A composite biomarker strategy integrating immune and tumor-intrinsic features may improve patient selection for ICIs.

2025-06-01·ESMO Open

First-in-human study of FAZ053, an anti-programmed death-ligand 1 (anti-PD-L1) monoclonal antibody, alone and in combination with spartalizumab (anti-PD-1), in patients with advanced malignancies

Article

作者: Bedard, P L ; Lai, C ; Janku, F ; Szpakowski, S ; Razak, A ; Subramanian, K ; Mataraza, J ; Kan, R ; Geva, R ; Chen, X ; Tan, D S P ; Takahashi, S ; Martin-Liberal, J ; Gucalp, A ; Reiners, R

BACKGROUND:

FAZ053 triggers an antitumor response by targeting programmed death-ligand 1 (PD-L1), thereby activating effector T cells and negatively regulating T cells. This study assessed the safety, tolerability, and preliminary efficacy of FAZ053 monotherapy and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors.

METHODS:

This phase I, multicenter, open-label study (NCT02936102) included dose escalation and dose expansion. The primary objectives were safety and tolerability; secondary objectives were pharmacokinetics, pharmacodynamics, and preliminary antitumor activity.

RESULTS:

Of the 154 patients treated, 49 (52.7%) patients receiving FAZ053 monotherapy experienced at least one treatment-related adverse event (TRAE), of whom 6 (6.5%) experienced grade ≥3 TRAEs; 35 patients (57.4%) receiving combination therapy experienced TRAEs, of whom 3 (4.9%) experienced grade ≥3 TRAEs. One patient who received FAZ053 1600 mg every 6 weeks (Q6W) and one who received FAZ053 20 mg every 3 weeks (Q3W) with spartalizumab 300 mg Q3W experienced dose-limiting toxicities of grade 4 creatinine increase and grade 3 liver function test increased, respectively. The median duration of exposure was 105 days for monotherapy and 85 days for combination therapy. During dose escalation, response was observed in 3 (5.1%) and 3 (4.9%) patients receiving FAZ053 monotherapy and combination therapy, respectively. In dose expansion, response was observed in 2 (50%) patients with advanced alveolar soft part sarcoma (ASPS) and 3 (30%) patients with advanced chordoma receiving FAZ053 monotherapy. FAZ053 demonstrated a dose-proportional pharmacokinetic profile with a terminal half-life of 20.6 days at 1200 mg Q3W. Biomarker analysis showed increased immune gene expression following FAZ053 treatment. The recommended dose for expansion was 1200 mg Q3W.

CONCLUSION:

FAZ053 monotherapy was well tolerated and effective in maintaining disease control in various tumors including ASPS and chordoma. The anticipated synergistic effect of combined programmed cell death protein 1 (PD-1) and PD-L1 inhibition was not observed. These findings contribute to the growing evidence that rare, phenotypically 'immune cold' sarcomas, such as ASPS and chordoma, can become responsive to immune checkpoint inhibitors.

48

项与 Spartalizumab 相关的新闻（医药）

2026-02-26

·药研界面

普递瑞完成天使+轮融资：打造差异化蛋白降解与互作的多机制创新引擎，攻克CNS与炎症难成药靶点

2月25日，致力于CNS与炎症相关疾病开发，构建差异化蛋白降解与互作药物的平台型生物科技公司普递瑞（Prodegre）完成数千万元天使+轮融资，由复容投资旗下复旦大学生物医药转化基金（以下简称“三复基金”）领投，公司核心团队持续跟投加注。本轮融资将重点用于加速Prodegre ATLAS™平台研发，推动帕金森病关键致病蛋白a-synuclein降解剂的首个剂型IND申报与口服优化工作。普递瑞基于以靶点为中心、多机制驱动的研发战略，自主构建了Prodegre ATLAS™差异化蛋白降解与互作平台。与传统降解技术依赖单一路线、单一E3 ligase不同，该平台通过多模态、多机制协同策略拓展降解药物的可及靶点空间，通过集成AI驱动的Degron识别和虚拟筛选，高效Warhead/E3配体设计，三元复合物DMPK优化的一体化流程，系统性提升降解剂开发效率，致力于实现降解剂从大规模筛选或偶然发现到理性设计的研发转型。 Prodegre ATLAS™核心技术布局包括：肽类降解剂（Peptide-based degrader）路径：该机制独立于传统CRBN依赖策略，通过三段式设计实现高效透膜、强靶向性及天然蛋白降解驱动。该途径不仅突破了 CRBN 的限制，还能够精准降解传统小分子难以成药的靶点，如a-synuclein这类内在无序蛋白（IDP）靶点。基于这一路径开发的候选分子PDR-001为全球首个推进临床阶段的only-in-class肽类降解药物。 2025年12月，PDR-001在上海交通大学医学院附属瑞金医院正式启动IIT临床研究小分子降解剂路径：针对明确机制且临床上缺乏高效口服新药的CNS与炎症靶点，普递瑞系统性布局了包括分子胶、口服PROTAC等具有优异患者依从性的 modality。平台将根据竞争格局与靶点属性灵活选择最优开发路径，提高临床成功概率及商业化优势。新E3 ligand开发：针对特定组织高表达的E3 ligase，普递瑞正致力于扩展可配体化的E3 ligase体系，利用多种生物与化学方法开发肽类/小分子E3配体。新E3配体储备将拓宽分子胶可降解的靶点范围，为构建更具特异性和广泛适用性的降解剂提供理性设计的关键驱动力。普递瑞创始人、董事长王玉田院士表示：“我们围绕机制创新驱动临床转化的战略，在平台设计上坚持多维度机制协同与靶点中心逻辑，真正将科研创新与产业化落地能力结合起来。Prodegre ATLAS™提升了传统降解药物的可达靶点范围，为CNS与炎症适应症提供新的治疗策略。本轮融资将加速平台迭代，吸引全球顶尖人才与战略合作伙伴，组建一流产业化团队。三复基金负责人李政雄表示：“普递瑞在差异化降解剂领域的技术深度与平台广度令人印象深刻。当前全球药物研发面临大量不可成药靶点带来的产业瓶颈，Prodegre ATLAS™所体现的多机制降解策略具有显著的差异化竞争力与产业价值。我们相信，普递瑞具备将这一创新平台转化为临床突破与产业化价值的实力。近期，我们也欣喜地看到全球龙头企业积极推进靶向a-synuclein蛋白管线，期待公司产品早日进入临床。”

2026-02-25

·张通社Invest

三复基金领投了，张江一家创新药研发企业！

张通社 zhangtongshe.com ｜立足张江，面向上海，服务科创｜普递瑞获得新一轮融资。出品 | 张通社首图 | 网络 2月25日，张通社团队获悉，普递瑞（上海）医药有限公司（简称“普递瑞”）宣布完成数千万元天使+轮融资，由复容投资旗下复旦大学生物医药转化基金（以下简称“三复基金”）领投，公司核心团队持续跟投加注。普递瑞融资历程 01 公司简介普递瑞成立于2023年，位于上海张江，公司基于以靶点为中心、多机制驱动的研发战略，自主构建了Prodegre ATLAS™差异化蛋白降解与互作平台。与传统降解技术依赖单一路线、单一E3 ligase不同，该平台通过多模态、多机制协同策略来拓展降解药物的可及靶点空间，通过集成AI驱动的Degron识别和虚拟筛选，高效Warhead/E3配体设计，三元复合物DMPK优化的一体化流程，系统性提升降解剂开发效率，致力于实现降解剂从大规模筛选或偶然发现到理性设计的研发转型。 Prodegre ATLAS™核心技术布局包括： ● 肽类降解剂（Peptide-based degrader）路径：该机制独立于传统CRBN依赖策略，通过三段式设计实现高效透膜、强靶向性及天然蛋白降解驱动。该途径不仅突破了 CRBN 的限制，还能够精准降解传统小分子难以成药的靶点，如a-synuclein这类内在无序蛋白（IDP）靶点。基于这一路径开发的候选分子PDR-001为全球首个推进临床阶段的only-in-class肽类降解药物。 ● 小分子降解剂路径：针对明确机制且临床上缺乏高效口服新药的CNS与炎症靶点，普递瑞系统性布局了包括分子胶、口服PROTAC等具有优异患者依从性的 modality。平台将根据竞争格局与靶点属性灵活选择最优开发路径，提高临床成功概率及商业化优势。 ● 新E3 ligand开发：针对特定组织高表达的E3 ligase，普递瑞正致力于扩展可配体化的E3 ligase体系，利用多种生物与化学方法开发肽类/小分子E3配体。新E3配体储备将拓宽分子胶可降解的靶点范围，为构建更具特异性和广泛适用性的降解剂提供理性设计的关键驱动力。 02 发展关键事件 2023年 • 8月普递瑞（上海）医药有限公司于2023年8月在上海浦东正式注册成立，由王玉田院士担任董事长，谭珅担任CEO。 • 12月在“2023浦东国际人才港论坛”上，普递瑞医药作为“浦东新区重大人才项目”代表参与集中签约，获得政府重点关注与资源支持。 2024年 • 4月宣布获得浦东创投（旗下科技创新投资基金）和联想创投的战略投资。这是公司的首轮融资，标志着其技术平台获得资本市场认可。 2025年 • 12月全球首创肽类蛋白降解剂 PDR-001 在上海交通大学医学院附属瑞金医院正式启动IIT（研究者发起的临床研究），并完成首例入组。该药针对帕金森病核心致病蛋白 α-synuclein。 2026年 • 2月由复容投资旗下三复基金领投，核心团队跟投。资金将用于加速 ATLAS™ 平台研发及 PDR-001 的 IND（新药临床试验申请）申报工作。 03 创始人介绍普递瑞（上海）医药有限公司的创始人是王玉田博士。教育经历：山东大学医学院医学学士；山东大学医学院生理学硕士；加拿大纽芬兰纪念大学神经科学博士。工作经历：加拿大皇家科学院院士，现任复旦—尚思神经科学院研究中心主任；曾任深圳理工大学生命健康学院院长、英属哥伦比亚大学终身教授；美国霍华德休斯医学研究所(HHMI)国际研究员。中国科学院海外评审专家。在脑中风、癫痫、药物成瘾等CNS疾病的病理机制和特异性药物开发中取得了一系列国际领先的成果，拥有多项国际保护的药物专利，多款药物进入临床开发阶段，具有深厚的全球医学与临床资源。【免责声明】本文所涉及内容仅为信息分享和事件讨论，不构成投资建议。 →若对稿件内容有异议，请联系张通社小助手+v：zts110_ ，说明公司及来意。更多融资并购需求半导体赛道生物医药赛道人工智能赛道具身智能赛道脑机接口赛道

蛋白降解靶向嵌合体引进/卖出

2026-02-25

·复容投资

复容投资领投「普递瑞」天使+轮融资，打造差异化蛋白降解与互作的多机制创新引擎

2月25日，致力于CNS与炎症相关疾病开发，构建差异化蛋白降解与互作药物的平台型生物科技公司普递瑞（Prodegre）完成数千万元天使+轮融资，由复容投资旗下复旦大学生物医药转化基金（以下简称“三复基金”）领投，公司核心团队持续跟投加注。本轮融资将重点用于加速Prodegre ATLAS™平台研发，推动帕金森病关键致病蛋白a-synuclein降解剂的首个剂型IND申报与口服优化工作。普递瑞基于以靶点为中心、多机制驱动的研发战略，自主构建了Prodegre ATLAS™差异化蛋白降解与互作平台。与传统降解技术依赖单一路线、单一E3 ligase不同，该平台通过多模态、多机制协同策略拓展降解药物的可及靶点空间，通过集成AI驱动的Degron识别和虚拟筛选，高效Warhead/E3配体设计，三元复合物DMPK优化的一体化流程，系统性提升降解剂开发效率，致力于实现降解剂从大规模筛选或偶然发现到理性设计的研发转型。 Prodegre ATLAS™核心技术布局包括：肽类降解剂（Peptide-based degrader）路径：该机制独立于传统CRBN依赖策略，通过三段式设计实现高效透膜、强靶向性及天然蛋白降解驱动。该途径不仅突破了 CRBN 的限制，还能够精准降解传统小分子难以成药的靶点，如a-synuclein这类内在无序蛋白（IDP）靶点。基于这一路径开发的候选分子PDR-001为全球首个推进临床阶段的only-in-class肽类降解药物。 2025年12月，PDR-001在上海交通大学医学院附属瑞金医院正式启动IIT临床研究小分子降解剂路径：针对明确机制且临床上缺乏高效口服新药的CNS与炎症靶点，普递瑞系统性布局了包括分子胶、口服PROTAC等具有优异患者依从性的 modality。平台将根据竞争格局与靶点属性灵活选择最优开发路径，提高临床成功概率及商业化优势。新E3 ligand开发：针对特定组织高表达的E3 ligase，普递瑞正致力于扩展可配体化的E3 ligase体系，利用多种生物与化学方法开发肽类/小分子E3配体。新E3配体储备将拓宽分子胶可降解的靶点范围，为构建更具特异性和广泛适用性的降解剂提供理性设计的关键驱动力。普递瑞创始人、董事长王玉田院士表示：“我们围绕机制创新驱动临床转化的战略，在平台设计上坚持多维度机制协同与靶点中心逻辑，真正将科研创新与产业化落地能力结合起来。Prodegre ATLAS™提升了传统降解药物的可达靶点范围，为CNS与炎症适应症提供新的治疗策略。本轮融资将加速平台迭代，吸引全球顶尖人才与战略合作伙伴，组建一流产业化团队。三复基金负责人李政雄表示：“普递瑞在差异化降解剂领域的技术深度与平台广度令人印象深刻。当前全球药物研发面临大量不可成药靶点带来的产业瓶颈，Prodegre ATLAS™所体现的多机制降解策略具有显著的差异化竞争力与产业价值。我们相信，普递瑞具备将这一创新平台转化为临床突破与产业化价值的实力。近期，我们也欣喜地看到全球龙头企业积极推进靶向a-synuclein蛋白管线，期待公司产品早日进入临床。” 普递瑞的更多故事

100 项与 Spartalizumab 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11605	Spartalizumab	-	DB14892

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
黑色素瘤	临床3期	美国	Novartis Pharmaceuticals Corp.	2017-02-17
黑色素瘤	临床3期	日本	Novartis Pharmaceuticals Corp.	2017-02-17
黑色素瘤	临床3期	加拿大	Novartis Pharmaceuticals Corp.	2017-02-17
黑色素瘤	临床3期	德国	Novartis Pharmaceuticals Corp.	2017-02-17
黑色素瘤	临床3期	匈牙利	Novartis Pharmaceuticals Corp.	2017-02-17
黑色素瘤	临床3期	意大利	Novartis Pharmaceuticals Corp.	2017-02-17
黑色素瘤	临床3期	荷兰	Novartis Pharmaceuticals Corp.	2017-02-17
黑色素瘤	临床3期	西班牙	Novartis Pharmaceuticals Corp.	2017-02-17
黑色素瘤	临床3期	瑞士	Novartis Pharmaceuticals Corp.	2017-02-17
转移性黑色素瘤	临床3期	意大利	Novartis Pharma AG	2017-02-07

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04736485 (GASPAR, Pubmed \| Eur J Cancer)	临床2期	胃癌	64	Spartalizumab + FLOT	網壓醖鏇鹹築網選膚製(壓膚鑰醖淵顧淵艱構遞) = 艱醖鹹齋選醖構範鏇膚積鬱積窪選鬱糧願襯糧 (艱齋鬱襯簾齋獵廠積觸 ) 更多	积极	2026-03-01
NCT04581343 (PanCAN-SR1, CTgov)	临床1期	转移性胰腺癌 \| 转移性胰腺导管腺癌	10	Canakinumab	繭願夢艱壓齋鹽窪選選 = 顧膚網鹹願顧窪鹽餘觸鏇壓蓋遞壓鑰網積鏇繭 (衊選廠餘鏇蓋糧廠糧鬱, 獵憲艱鹹艱壓淵網築廠 ~ 顧鑰醖構壓憲艱繭壓觸) 更多	-	2025-04-08
NCT03668431 (NEWS) 人工标引	临床2期	BRAF V600E突变结直肠癌 BRAF V600E	37	Dabrafenib + Trametinib + Spartalizumab	齋築顧鬱醖鹹積鹹鹽糧(鬱構觸願鏇憲網鑰壓蓋) = 簾艱衊醖網糧鏇願製鹽齋醖範淵窪壓廠選築壓 (壓襯淵構鏇遞鏇艱糧醖 ) 更多	积极	2025-03-01
NCT04310397 (CTgov)	临床2期	BRAF V600K 阳性黑色素瘤 \| 皮肤黑色素瘤	4	Dabrafenib+trametinib+Spartalizumab	網繭遞艱遞餘夢積鹽鏇(網膚壓齋築選鑰簾糧簾) = 鬱範鹹鑰醖淵鑰遞蓋顧製醖範糧窪製顧範構窪 (淵範醖鑰淵範廠製選繭, 艱餘齋膚願齋鑰積範積 ~ 鏇積顧夢蓋製夢窪顧淵) 更多	-	2024-10-30
NCT03064854 (not available, Pubmed \| BMC Cancer) 人工标引	临床1期	转移性非小细胞肺癌一线	-	Spartalizumab 300 mg Q3W + Gemcitabine/Cisplatin	觸衊構餘選艱衊鑰窪壓(製膚衊淵願築觸鏇鏇鹹) = 簾鹽築積醖夢鏇夢廠鬱遞壓壓艱鹹醖廠醖觸淵 (憲築蓋夢膚積築顧顧鬱 ) 更多	积极	2024-10-24
				Spartalizumab 300 mg Q3W + Pemetrexed/Cisplatin	觸衊構餘選艱衊鑰窪壓(製膚衊淵願築觸鏇鏇鹹) = 觸鹽願積窪鏇淵繭築夢遞壓壓艱鹹醖廠醖觸淵 (憲築蓋夢膚積築顧顧鬱 ) 更多
NCT04544111 (ESMO2024) 人工标引	临床2期	难治性甲状腺癌	19	TrametinibPDR001	憲壓餘鹹憲襯艱衊鹹製(夢願顧夢醖夢鹹鹹願壓) = 襯鑰夢鬱衊鑰網積廠鑰鑰鏇膚鹹淵選選餘餘齋 (鑰衊餘築醖製鑰築蓋觸 ) 更多	积极	2024-09-16
				dabrafenib+PDR001 (BRAFV600E- tumors after progression on BRAF-directed therapy)	憲壓餘鹹憲襯艱衊鹹製(夢願顧夢醖夢鹹鹹願壓) = 憲糧繭獵製壓願簾襯鏇鑰鏇膚鹹淵選選餘餘齋 (鑰衊餘築醖製鑰築蓋觸 ) 更多
NCT04323436 (CTgov)	临床2期	非小细胞肺癌	31	Spartalizumab+Capmatinib (Run-in Part: Capmatinib 400 mg BID + Spartalizumab 400 mg Q4W)	襯獵積艱衊襯糧鹽齋膚 = 獵繭糧構選壓夢顧繭淵衊鹹鏇糧觸憲淵齋鑰艱 (鑰築獵築鬱鹽積餘齋鬱, 衊廠選願積襯鹹糧窪製 ~ 構壓壓夢壓齋簾觸艱範) 更多	-	2024-02-06
				Spartalizumab+Capmatinib (Run-in Part: Capmatinib 400mg BID + Spartalizumab 400mg Q4W (Prior Discontinuing Spartalizumab))	鏇淵襯範網鹽積簾鹽衊(憲獵糧範鏇鹽鬱艱顧鹹) = 艱構襯築範蓋蓋窪選窪構鹹選憲醖鬱鹽觸衊艱 (襯鏇觸壓築鹹鹽廠製衊, 繭鹹餘遞蓋齋醖繭夢構 ~ 醖襯壓膚壓膚願糧積顧) 更多
NCT03785496 (KCSG HN18-17 \| K-MASTER project 12, Pubmed) 人工标引	临床2期	食管鳞状细胞癌	44	Spartalizumab 300 mg	夢範蓋襯壓選淵獵願顧(淵蓋壓鹽鏇夢範醖範鏇) = 窪願淵繭遞膚構襯醖簾憲壓築齋鬱艱積獵餘壓 (醖憲獵襯獵齋積網齋選, 8.5 ~ 32.4) 更多	积极	2024-01-01
NCT02795429 (Pubmed) 人工标引	临床1/2期	肝细胞癌二线	62	Capmatinib 40Spartalizumabartalizumab 300 mg q3w	憲積憲廠衊築醖繭壓廠(鹽製夢淵醖醖餘鹽積鏇) = 簾鏇積願餘鏇觸觸淵蓋壓艱壓廠範選範憲簾網 (窪餘鏇願遞艱製鑰艱選 )	不佳	2024-01-01
				Spartalizumab alone	憲積憲廠衊築醖繭壓廠(鹽製夢淵醖醖餘鹽積鏇) = 鹹遞鏇觸築構糧艱鏇鹹壓艱壓廠範選範憲簾網 (窪餘鏇願遞艱製鑰艱選 )
NCT04736485 (GASPAR, ESMO 12023 \| ESMO 22023) 人工标引	临床2期	胃癌一线	67	spartalizumab + fluorouracil+leucovorin+oxaliplatin+ docetaxel	築鬱鹽膚淵網鹹遞積鏇(鹽製蓋願遞憲壓築繭蓋) = 簾衊艱願鑰鑰鏇夢構鹽鹹憲鹽鏇繭鑰獵觸憲衊 (艱膚醖願顧顧願繭艱廠 ) 更多	积极	2023-10-23
				spartalizumab + fluorouracil+leucovorin+oxaliplatin+ docetaxel (operative)	廠範顧窪築選餘範膚獵(鏇顧鹽夢淵顧窪艱構製) = 糧鹽廠願憲積餘繭積遞齋廠夢艱願鬱選艱顧遞 (積襯夢簾獵鏇齋蓋鑰製 ) 更多